Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00604890 · ClinicalTrials.gov registry record · Phase 1
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
A Phase 1 study, sponsored by BPGbio.
- Completed
- Registry status
- Phase 1
- Development phase
- 186
- Enrollment target
NCT00604890 is a Phase 1 study that has completed, run by BPGbio. The registered enrollment target is 186 participants.
The verdict
NCT00604890, a Phase 1 study, has completed, sponsored by BPGbio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 186 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of pharmaceutical compound (API 31510) topical cream topically applied to superficial basal cell carcinomas to obtain preliminary efficacy data for the treatment of superficial basal cell carcinomas by API 31510 topical cream. The study population will include one hundred and sixty (160) otherwise healthy male or female adults with one or more histologically confirmed superficial basal cell carcinoma lesions. One target lesion with an area of less than one inch will be designated for study treatment.
Interventions
- OTHER Placebo
- DRUG API 31510 3% Topical Cream
- DRUG API 31510 1.5% Topical Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2008-03 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00604890
The ClinicalTrials.gov registry entry for NCT00604890 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BPGbio, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00604890 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00604890 about?
NCT00604890 is a clinical study titled "Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma". The purpose of this study is to determine the safety and tolerability of pharmaceutical compound (API 31510) topical cream topically applied to superficial basal cell carcinomas to obtain preliminary efficacy data for the treatment of superficial basal cell carcinomas by API 31510 topical cream. The...
What is the current status of trial NCT00604890?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 186 participants. The study started on 2008-03. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00604890?
The interventions under investigation include: Placebo (OTHER), API 31510 3% Topical Cream (DRUG), API 31510 1.5% Topical Cream (DRUG).
Who is sponsoring clinical trial NCT00604890?
This trial is sponsored by BPGbio, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.